Taladegib
- Generic Name
- Taladegib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24F4N6O
- CAS Number
- 1258861-20-9
- Unique Ingredient Identifier
- QY8BWX1LJ5
- Background
Taladegib has been used in trials studying the treatment of Solid Tumor, COLON CANCER, BREAST CANCER, Advanced Cancer, and Rhabdomyosarcoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05817240
- Locations
- ๐ฆ๐บ
Research Site, Adelaide, South Australia, Australia
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04968574
- Locations
- ๐ฒ๐ฝ
Research Site, Puebla, Mexico
๐ฐ๐ทResearch Site (Bundang District), Seongnam, Korea, Republic of
๐ฐ๐ทResearch Site (Namdong District), Incheon, Korea, Republic of
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 94
- Registration Number
- NCT02784795
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธSylvester Comprehensive Cancer Center, Miami, Florida, United States
๐บ๐ธKarmanos Cancer Institute, Detroit, Michigan, United States
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT02530437
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
A Study in Advanced Cancer
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 84
- Registration Number
- NCT01226485
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tyler, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.